Clostridium difficile infection in 2010: advances in pathogenesis, diagnosis and management of CDI

Nat Rev Gastroenterol Hepatol. 2011 Feb;8(2):67-8. doi: 10.1038/nrgastro.2010.215.

Abstract

Clostridium difficile infection (CDI) publications have advanced in 2010 at a pace paralleling the increased frequency and severity of clinical infection. Both toxins A and B are essential virulence factors, pcr diagnostic testing is rapid, sensitive and specific, and recurrent CDI can be prevented using monoclonal antibodies to toxins A and B.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Aminoglycosides / therapeutic use
  • Antibodies, Monoclonal / therapeutic use
  • Bacterial Proteins / immunology
  • Bacterial Proteins / physiology
  • Bacterial Toxins / immunology
  • Clostridioides difficile* / genetics
  • DNA, Bacterial / genetics
  • Enterocolitis, Pseudomembranous* / diagnosis
  • Enterocolitis, Pseudomembranous* / drug therapy
  • Enterocolitis, Pseudomembranous* / etiology
  • Enterotoxins / immunology
  • Enterotoxins / physiology
  • Fidaxomicin
  • Humans
  • Reverse Transcriptase Polymerase Chain Reaction

Substances

  • Aminoglycosides
  • Antibodies, Monoclonal
  • Bacterial Proteins
  • Bacterial Toxins
  • DNA, Bacterial
  • Enterotoxins
  • tcdA protein, Clostridium difficile
  • toxB protein, Clostridium difficile
  • Fidaxomicin